Vous avez cherché: panitumumab (Anglais - Slovène)

panitumumab + folfiri
panitumumab in folfiri

each vial contains 400 mg panitumumab.
ena viala vsebuje 400 mg panitumumaba.

each vial contains 100 mg of panitumumab.
ena viala vsebuje 100 mg panitumumaba.

it contains the active substance panitumumab.
vsebuje zdravilno učinkovino panitumumab.

each ml of concentrate contains 20 mg panitumumab.
en mililiter koncentrata vsebuje 20 mg panitumumaba.

the active substance is panitumumab 20 mg/ ml.
zdravilna učinkovina je panitumumab 20 mg/ ml.

vectibix 20 mg/ ml sterile concentrate panitumumab iv
vectibix 20 mg/ ml sterilen koncentrat panitumumab i. v.

there was an increase in mortality in the panitumumab arm.
umrljivost v kraku s panitumumabom se je povečala.

vectibix 20 mg/ml concentrate for solution for infusion panitumumab
vectibix 20 mg/ml koncentrat za raztopino za infundiranje panitumumab

colourless solution that may contain visible amorphous panitumumab particles.
brezbarvna raztopina, ki lahko vsebuje vidne amorfne delce panitumumaba.

it is unknown whether panitumumab is excreted in human breast milk.
ni znano, ali se panitumumab pri človeku izloča v materinem mleku.

the active substance in vectibix, panitumumab, is a monoclonal antibody.
zdravilna učinkovina v zdravilu vectibix, panitumumab, je monoklonsko protitelo.

panitumumab does not seem to work in tumour cells that contain mutated ras genes.
zdi se, da panitumumab ne deluje pri tumorskih celicah, ki vsebujejo mutirani gen ras.

because human igg is secreted into human milk, panitumumab might also be secreted.
ker se v materino mleko izločajo humani igg, bi se lahko izločal tudi panitumumab.

this may be due to patients receiving panitumumab after progression among those randomized to bsc.
to gre morda na račun bolnikov, randomiziranimi na npo, ki so po napredovanju dobivali panitumumab.

each vial contains either 100 mg of panitumumab in 5 ml, or 400 mg of panitumumab in 20 ml.
ena viala vsebuje 100 mg panitumumaba v 5 ml ali 400 mg panitumumaba v 20 ml.

skin reactions were the most frequently occurring adverse reactions in patients receiving panitumumab in combination with chemotherapy.
med bolniki, ki so prejemali panitumumab v kombinaciji s kemoterapijo, so bili najpogostejši neželeni učinki kožne reakcije.

panitumumab binds to the ligand binding domain of egfr and inhibits receptor autophosphorylation induced by all known egfr ligands.
panitumumab se veže na predel egfr za vezavo liganda in zavre avtofosforilacijo receptorja, ki jo sprožijo vsi znani ligandi egfr.

the stable disease rates in the kras mutant group were 12% for panitumumab and 8% for bsc.
v skupini z mutiranim kras pa je bil delež stabilne bolezni s panitumumabom 12% in z najboljšo podporno oskrbo 8%.

each single-use vial contains either 100 mg of panitumumab in 5 ml, or 400 mg of panitumumab in 20 ml.
ena viala za enkratno uporabo vsebuje 100 mg panitumumaba v 5 ml ali 400 mg panitumumaba v 20 ml.